Last reviewed · How we verify
NCT05995704
Evaluation of Apraglutide on Gastric Emptying
Phase 1 trial testing Apraglutide in Healthy Subjects in 42 participants. Completed in 24 July 2023.
24 July 2023
Quick facts
| Lead sponsor | VectivBio AG |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | other |
| Enrollment | 42 |
| Start date | 2 March 2023 |
| Primary completion | 24 July 2023 |
| Estimated completion | 24 July 2023 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Apraglutide — full drug profile →
- Placebo
- Acetaminophen (Paracetamol) — full drug profile →
Conditions studied
- Healthy Subjects — all drugs for Healthy Subjects →
Sponsor
VectivBio AG — full company profile →
Who can join
Adults 18 to 45, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective is to assess the effect of apraglutide on gastric emptying of liquids in healthy subjects, as measured by the PK of acetaminophen mixed with a liquid meal.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05995704
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Apraglutide
Trials testing the same drug.
- NCT06002555 — Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation · Phase 1 · completed
- NCT05706623 — A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Norm · Phase 1 · completed
- NCT05415410 — Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD) · Phase 2 · terminated
- NCT05018286 — Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. · Phase 3 · active not recruiting
- NCT04964986 — Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-C · Phase 2 · completed
Other recruiting trials for Healthy Subjects
Currently open trials in the same condition.
- NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
- NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
- NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
- NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
- NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting
Other VectivBio AG trials
Trials by the same sponsor.
- NCT06002555 — Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation · Phase 1 · completed
- NCT05706623 — A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Norm · Phase 1 · completed
- NCT05415410 — Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD) · Phase 2 · terminated
- NCT05018286 — Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. · Phase 3 · active not recruiting
- NCT04964986 — Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-C · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05995704 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VectivBio AG
- Last refreshed: 24 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05995704.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing